Jeff Yass’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $577K | Sell |
65,961
-1,113,315
| -94% | -$8.43M | ﹤0.01% | 9576 |
|
|
2026
Q1 | $9.05M | Sell |
1,179,276
-2,475,223
| -68% | -$16.9M | ﹤0.01% | 3271 |
|
|
2025
Q4 | $7.24M | Buy |
3,654,499
+1,011,845
| +38% | +$2.29M | ﹤0.01% | 3488 |
|
|
2025
Q3 | $6.5M | Buy |
2,642,654
+790,746
| +43% | +$2.04M | ﹤0.01% | 3676 |
|
|
2025
Q2 | $4.89M | Buy |
1,851,908
+1,078,437
| +139% | +$2.9M | ﹤0.01% | 4013 |
|
|
2025
Q1 | $2.33M | Buy |
773,471
+209,560
| +37% | +$635K | ﹤0.01% | 5188 |
|
|
2024
Q4 | $1.44M | Buy |
563,911
+145,854
| +35% | +$608K | ﹤0.01% | 6042 |
|
|
2024
Q3 | $1.56M | Buy |
418,057
+38,956
| +10% | +$180K | ﹤0.01% | 5824 |
|
|
2024
Q2 | $2.4M | Buy |
379,101
+267,713
| +240% | +$1.77M | ﹤0.01% | 4735 |
|
|
2024
Q1 | $598K | Sell |
111,388
-74,652
| -40% | -$338K | ﹤0.01% | 8077 |
|
|
2023
Q4 | $934K | Sell |
186,040
-271,592
| -59% | -$852K | ﹤0.01% | 7147 |
|
|
2023
Q3 | $773K | Buy |
457,632
+97,419
| +27% | +$196K | ﹤0.01% | 7219 |
|
|
2023
Q2 | $1M | Sell |
360,213
-74,960
| -17% | -$212K | ﹤0.01% | 6677 |
|
|
2023
Q1 | $792K | Buy |
435,173
+13,174
| +3% | +$41K | ﹤0.01% | 7438 |
|
|
2022
Q4 | $2.14M | Sell |
421,999
-208,767
| -33% | -$1.15M | ﹤0.01% | 4574 |
|
|
2022
Q3 | $3.13M | Buy |
630,766
+56,047
| +10% | +$255K | ﹤0.01% | 3997 |
|
|
2022
Q2 | $2.14M | Sell |
574,719
-190,221
| -25% | -$764K | ﹤0.01% | 4775 |
|
|
2022
Q1 | $4.29M | Sell |
764,940
-184,486
| -19% | -$1.13M | ﹤0.01% | 3907 |
|
|
2021
Q4 | $5.77M | Buy |
949,426
+63,982
| +7% | +$481K | ﹤0.01% | 3505 |
|
|
2021
Q3 | $8.62M | Buy |
885,444
+120,263
| +16% | +$1.32M | ﹤0.01% | 3085 |
|
|
2021
Q2 | $10.9M | Buy |
765,181
+294,954
| +63% | +$4.87M | ﹤0.01% | 2787 |
|
|
2021
Q1 | $11.2M | Buy |
470,227
+152,104
| +48% | +$3.94M | ﹤0.01% | 2607 |
|
|
2020
Q4 | $4.24M | Buy |
318,123
+156,498
| +97% | +$1.51M | ﹤0.01% | 3696 |
|
|
2020
Q3 | $1.12M | Sell |
161,625
-211,833
| -57% | -$2.11M | ﹤0.01% | 5832 |
|
|
2020
Q2 | $4.59M | Buy |
373,458
+13,003
| +4% | +$73.4K | ﹤0.01% | 3120 |
|
|
2020
Q1 | $1.04M | Buy |
360,455
+227,525
| +171% | +$1.14M | ﹤0.01% | 5320 |
|
|
2019
Q4 | $504K | Buy |
+132,930
| New | +$226K | ﹤0.01% | 6969 |
|
|
2019
Q3 | – | Sell |
-11,217
| Closed | -$11K | – | 10453 |
|
|
2019
Q2 | $11K | Buy |
+11,217
| New | +$12.9K | ﹤0.01% | 10064 |
|
|
2019
Q1 | – | Sell |
-29,933
| Closed | -$37.6K | – | 9288 |
|
|
2018
Q4 | $35K | Buy |
+29,933
| New | +$68.5K | ﹤0.01% | 8579 |
|
|
2018
Q3 | – | Sell |
-26,837
| Closed | -$82K | – | 9666 |
|
|
2018
Q2 | $82K | Buy |
26,837
+13,509
| +101% | +$50K | ﹤0.01% | 9122 |
|
|
2018
Q1 | $52K | Sell |
13,328
-648
| -5% | -$2.84K | ﹤0.01% | 8940 |
|
|
2017
Q4 | $63K | Sell |
13,976
-39,692
| -74% | -$188K | ﹤0.01% | 8846 |
|
|
2017
Q3 | $294K | Buy |
+53,668
| New | +$331K | ﹤0.01% | 7431 |
|
|
2017
Q2 | – | Sell |
-49,411
| Closed | -$213K | – | 9449 |
|
|
2017
Q1 | $175K | Sell |
49,411
-3,688
| -7% | -$18.2K | ﹤0.01% | 8109 |
|
|
2016
Q4 | $304K | Buy |
+53,099
| New | +$354K | ﹤0.01% | 7948 |
|
|
2016
Q3 | – | Sell |
-43,885
| Closed | -$328K | – | 8687 |
|
|
2016
Q2 | $273K | Buy |
43,885
+23,838
| +119% | +$185K | ﹤0.01% | 7109 |
|
|
2016
Q1 | $165K | Buy |
20,047
+8,906
| +80% | +$83.9K | ﹤0.01% | 8137 |
|
|
2015
Q4 | $193K | Sell |
11,141
-18,452
| -62% | -$274K | ﹤0.01% | 8454 |
|
|
2015
Q3 | $339K | Buy |
+29,593
| New | +$646K | ﹤0.01% | 7836 |
|
Other funds holding IBRX
Jeff Yass's IBRX Position: Q2 2026 in Review
Jeff Yass reduced its ImmunityBio (IBRX) stake by 94% in Q2 2026, selling an estimated $8.43M and leaving 65,961 shares worth $577K. The position accounts for ﹤0.01% of the portfolio, ranked #9576.
Jeff Yass first reported a position in IBRX in Q3 2015 and has held it in 39 quarters since. The position peaked at $11.2M in Q1 2021. 403 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.
- Jeff Yass held 65,961 shares of ImmunityBio worth $577K as of Q2 2026.
- Jeff Yass sold 1,113,315 ImmunityBio shares in Q2 2026, an estimated $8.43M.
- ImmunityBio made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #9576 holding.
- Jeff Yass first reported a position in ImmunityBio in Q3 2015 and has held it in 39 quarters since.
- Jeff Yass's ImmunityBio position peaked at $11.2M in Q1 2021.
- 403 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.